Redeye comments on Moberg Pharma’s Q3 report, in which sales came in slightly ahead of our forecast ...
Redeye notes that InfraCom’s Q3 2025 report aligned with net sales estimates, but EBITDA was weighed...
Redeye provides an update following Scibase’s Q3 report and intensive news flow last Friday.
BeammWave's Q3 report was in line with expectations, the most notable event being the rights issue t...
Redeye initiates coverage of VEF, a specialised investment company that offers rare public market ac...
* Q3 Paper EBIT of ~PLN 16m vs. our PLN 5m * Challenging markets * Fair value range of SEK 17-60 Q3 ...
Investors House's Q3 report was the first since the divestment of the Apitare JV, of which Investors...
* Customer caution weighing on estimates * We lower '25e-'27e sales by 11-4% and adj.
Redeye comments on qbeyond’s Q3 report showing softer underlying figures than we expected.
Redeye initiates coverage of Freja eID Group, a technology platform offering various e-ID solutions ...
Redeye sees the phase I results from the controlled study of semaglutide monthly depot as a success,...
Redeye comments on the resignation of Kontigo Care’s CEO.
Redeye returns with an update following Ascelia Pharma's Q3 update, which contained no surprises.
RaySearch’s Q3 increases our confidence in its potential for profitable sales growth, with accelerat...
Redeye updates its estimates and valuation following Catella’s Q3 2025 report.
Redeye presents its preview for Paxman’s Q3 2025 report, due on November 14.
* We update our model after the announced divestment of Public * Extraordinary dividend on the cards...
* Orders grow 25%, sales 14%, adj. EBITA margin up 0.
Adtraction redovisade minskad nettoomsättning och ökad EBITA i det tredje kvartalet.
Redeye comments on Active Biotech's third quarter report.
